ArticlePloS one2008
Pharmacotherapy of schizophrenic patients: preponderance of off-label drug use.
Article in PloS one, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 64 citations in OpenAlex.
- Antipsychotic treatment patterns and predictors of polypharmacy in psychotic disorders: 20-year real-world data from a tertiary center.Irish journal of medical science · 2026Article
- Prescribing Trends for the Same Patients with Schizophrenia Over 20 Years.Neuropsychiatric disease and treatment · 2023Article
- Off-label use of antidepressants, antipsychotics, and mood-stabilizers in psychiatry.Journal of neural transmission (Vienna, Austria : 1996) · 2022Article
- Psychopharmacological Treatment of Schizophrenia Over Time in 30 908 Inpatients: Data From the AMSP Study.The international journal of neuropsychopharmacology · 2019Article
- Psychotropic drug-prescribing correlates of disorganized speech in Asians with schizophrenia: The REAP-AP study.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2019Article
- Article
- Analysis of the Health Insurance Review and Assessment Service data from 2011 to 2015.International journal of mental health systems · 2018Article
- Striatal cholinergic interneurons and D2 receptor-expressing GABAergic medium spiny neurons regulate tardive dyskinesia.Experimental neurology · 2016Article
- Trends in the access to and the use of antipsychotic medications and psychotropic co-treatments in Asian patients with schizophrenia.Epidemiology and psychiatric sciences · 2016Article
- Bridging the gap between education and appropriate use of benzodiazepines in psychiatric clinical practice.Neuropsychiatric disease and treatment · 2015Review
- Off-label use of sodium valproate for schizophrenia.PloS one · 2014Article
- Second generation antipsychotic-induced type 2 diabetes: a role for the muscarinic M3 receptor.CNS drugs · 2013Review
- Description of long-term polypharmacy among schizophrenia outpatients.Social psychiatry and psychiatric epidemiology · 2013Article
- Antipsychotic polypharmacy in a regional health service: a population-based study.BMC psychiatry · 2012Article
- Off-label use of atypical antipsychotics: cause for concern?CNS drugs · 2012Article
- Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain.PloS one · 2012Article
- Treatment-resistant Schizophrenia: Evidence-based Strategies.Mens sana monographs · 2012Article
- [Polypharmacy in schizophrenia].Der Nervenarzt · 2011Article
- A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy.Journal of psychiatry & neuroscience : JPN · 2009Review
- Use of Benzodiazepines and Antipsychotic Drugs Are Inversely Associated With Acute Readmission Risk in Schizophrenia.Journal of clinical psychopharmacologyObservational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Multiple drug class combinations are often prescribed for the treatment of schizophrenia, although antipsychotic monotherapy reflects FDA labeling and scientific justification for combinations is highly variable. This study was performed to gain current data regarding drug treatment of schizophrenia as practiced in the community and to assess the frequencies of off-label drug class combinations. 200 DSM IV-diagnosed schizophrenic patients recruited from community treatment sources participated in this cross-sectional study of community based schizophrenic patients. Drug class categories include First and Second Generation Antipsychotic drugs (FGA and SGA, respectively), mood stabilizers, antidepressants and anti-anxiety drugs. 25.5% of patients received antipsychotic monotherapy; 70% of patients received an antipsychotic and another drug class. A total of 42.5% of patients received more than one antipsychotic drug. The most common drug class combination was antipsychotic and a mood stabilizer. Stepwise linear discriminant function analysis identified the diagnosis of schizoaffective schizophrenia, history of having physically hurt someone and high scores on the General Portion of the PANSS rating scale predicted the combined use of an antipsychotic drug and a mood stabilizer. "Real world" pharmacotherapy of schizophrenia has developed its own established practice that is predominantly off-label and may have outstripped current data support. The economic implications for public sector payers are substantial as well as for the revenue of the pharmaceutical industry, whose promotion of off-label drug use is an increasingly problematic. These data are consistent with the recognition of the therapeutic limitations of both first and second generation antipsychotic drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.